Break Boundaries. Ignite Change. Nasdaq: IOBT Corporate Presentation January 2024 Exhibit 99.1
DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business plan, clinical trials and regulatory submissions. We may, in some cases, use terms such as “may,” “should,” “would,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the execution of our business plan, success and timing of our clinical trials or other studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Indications: Melanoma SCCHN NSCLC 3 T-win cancer vaccine technology platform 1 3 Pipeline programs 17 Patent Families Focused on improving clinical effect without adding systemic toxicity 50% 80% * Results from phase 1/2 MM1636 Melanoma 25.5 Months mPFS* Providing rapid and durable responses HIGHLIGHTS | Break Boundaries. Ignite Change. 3Q24 Ph. 3 interim analysis outcome IO102-IO103 in Ph. 3 Pivotal trial in advanced melanoma fully enrolled 2025 Potential US market entry ORR* CRR*
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
PATIENT FOCUS | Improving patient outcomes without adding systemic toxicity on both advanced and earlier stages of cancer * IOBT is also present in two other indications: Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Non-Small Cell Lung Cancer Treatment (NSCLC) ** Results from phase 1/2 MM1636 Melanoma Sources: Cancer.net Editorial Board 2023 Evolving focus IO102 – IO103 vaccine in neo-adjuvant / adjuvant Exploring treatment with a curable intent and applicable to earlier stages of cancer IO BIOTECH’S FOCUS WITH IO102-IO103 IN MELANOMA* Current focus IO102 – IO103 vaccine in advanced melanoma The phase 1/2 trial in metastatic melanoma showed a nearly doubling of the expected activity of anti-PD1 alone, with no added systemic toxicity (80% ORR**) AN UNMET NEED < Diagnosis 16% of all diagnosed Advanced melanoma treatment paradigm Surgery (if applicable) Stage III/IV cancer There is a need for therapeutic strategies that can continue to improve patient outcomes, with novel mechanisms of action to optimize treatment response without adding systemic toxicity.
MARKET | IO Biotech aims to address the unmet need in 3 large and growing indications Squamous Cell Carcinoma of the Head and Neck* (SCCHN) Non-Small Cell Lung Cancer Treatment** (NSCLC) Melanoma New cases, worldwide Deaths, worldwide New cases, worldwide Deaths, worldwide New cases, worldwide Deaths, worldwide 2020 Estimation for 2040 ~510 000 ~325,000 ~57,000 ~96,000 ~744,000 1,109,000 ~364,000 ~1,875,000 ~3,084,000 ~1,526,000 ~556,000 ~2,557,000 +57% +68% +49% +52% +64% +68% *Data represented here is a sum of incidence of Lip, Oral Cavity, Larynx, Hypopharynx, and Oropharynx cancer ** Data represented here corresponds to 85% of the incidence of trachea, bronchus and lung. Sources: International agency for research on cancer
2028 2022 16 14 12 10 8 6 4 2 +11% 2028 2022 2028 2022 Forecast global Melanoma Drug Sales in USD billions Forecast global SCCHN Drug Sales in USD billions Forecast global NSCLC Drug Sales in USD billions 0.0 4.0 5.0 4.5 3.5 3.0 2.5 2.0 1.5 1.0 0.5 +8% 0 90 80 70 60 50 40 30 4.3 9.0 5.4 3.3 20 10 +10% CAGR 30.0 54.4 27.0 15.5 14.4 7.6 2.9 4.7 CAGR 45.5 81.4 CAGR MARKET | Expected growth in global cancer drug sales for 2028 indicates a need for new and effective treatments Key takeaways: All three indications are projected to grow at a similar rate (CAGR between 8% and 11%) with Melanoma having the fastest estimated growth rate. NSCLC has the highest projected market value and given its large market size, even a small market share could be substantial. US US US Source: Evaluate Pharma accessed December 2023
MARKET | Solid tumors are often detected at advanced stages, or progressing quickly to advanced stage, increasing the mortality rate ~325,000 New cases in 2020, worldwide ~57,000 Deaths in 2020, worldwide ~744,000 New cases in 2020, worldwide ~364,000 Deaths in 2020, worldwide Melanoma Non-Small Cell Lung Cancer Treatment** (NSCLC) Squamous Cell Carcinoma of the Head and Neck* (SCCHN) ~1,875,000 New cases in 2020, worldwide ~1,526,000 Deaths in 2020, worldwide Global cancer incidence Worldwide, lung cancer is the 2nd most diagnosed cancer and NSCLC is estimated to account for 85% of all lung cancer diagnoses 5-year survival rate The 5-year survival rate for patients in stage IV is 22.5%1 The 5-year survival rate is 50%2 The 5-year relative survival rate for patients in stage IV is 28% 3 Stages at diagnosis Stage I/II and III/IV melanoma accounts for 84% and 16% of the new cases, respectively Stage I/II, III and IV SCCHN accounts for 28%, 55% and 17% of the new cases, respectively Stage I, II, III and IV lung cancer accounts for 21%, 5%, 23% and 44% of the new cases, respectively Worldwide, SCCHN is the 6th most diagnosed cancer Worldwide, melanoma is the 17th most diagnosed cancer and 5th most common cancer in the US *Data represented here is a sum of incidence of Lip, Oral Cavity, Larynx, Hypopharynx, and Oropharynx cancer ** Data represented here corresponds to 85% of the incidence of trachea, bronchus and lung. Source: International agency for research on cancer 1. Melanoma Research Alliance; 2. National Library of Medicine, The Journal of Pain 3. Cancer.Net
MARKET | Melanoma, SCCHN, and NSCLC are worldwide cancer threats, but especially present in Europe, North America and Oceania 16,1 Northern America Oceania Europe 9,0 Melanoma SCCHN NSCLC 27,71 11,4 11,0 25,0 30,1 11,2 20,4 Asia 0,4 8,1 19,5 Melanoma, SCCHN, and NSCLC incidence in 2020, age standardized rate (ASR) per 100,000 Key takeaways: Worldwide, melanoma is the 17th most diagnosed cancer and 5th most common cancer in the US Worldwide, SCCHN is the 6th most diagnosed cancer (sum of Lip, Oral Cavity, Larynx, Hypopharynx, and Oropharynx cancer) Worldwide, lung is the 2nd most diagnosed cancer and NSCLC is estimated to account for 85% of all lung cancer diagnoses Latin America and the Caribbean 2,3 5,8 10,2 Africa 0,9 3,7 5,3 *Germany, France, Italy, Spain, UK Sources: GLOBOCAN, International Agency for Research Cancer, 2020
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
Clinical POC Enhanced activity outcomes when administered in combination with anti PD-1 therapy high ORR of 80%, with 50% of patients reaching a CR Duration of response demonstrated rapid and durable responses No added systemic toxicity Favorable safety & tolerability Safety profile of IO102-IO103 combined with anti PD-1 in Ph 1/2 comparable to anti-PD-1 mono therapy Broad applicability Responses across patient subgroups BRAF mutation, PD-L1 status, LDH. Minimized time to treatment Preparation and administration designed as readily available off-the shelf vaccine providing immediate treatment within the optimal therapeutic window compared to personalized approaches T-win® cancer vaccine technology platform with a dual mechanism of action Targets both the tumor and the immuno- suppressive cells in the TME Enhanced activity by modulating the TME and creating a more pro-inflammatory environment Multi-dimensional level Potential to broad application to different indications (different cancer types) Advances the IO treatment paradigm Clinical data showing activity without added systemic toxicity T-win® cancer vaccine technology platform with a dual mechanism of action Time to treatment Off-the-shelf therapeutic cancer vaccines Unique Value Proposition PROOF POINTS PROOF POINTS PROOF POINTS *HCPs = healthcare professionals Sources: Munir et al. 2012; Munir et al. 2013; Ahmad et al. 2014 ;Andersen 2019 ; Kjeldsen et al, 2021 UNIQUE VALUE PROPOSITION | T-Win® investigational IO102-IO103 cancer vaccine with dual mechanism of action and POC with high clinical efficacy
UNIQUE VALUE PROPOSITION | Preliminary physician feedback highlights from market research the potential of IO Biotech’s vaccine IO102-IO103 The mOS is the most impressive data presented - the 16 months improvement is excellent – FR KOL (if) the ORR is superior to ipi + nivo, this product will become the new standard of care – US KOL I would probably use this for all my patients regardless of BRAF or PD-L1 status – US KOL Excited to help more patients and see how benefit would be in long term - KOL Encouraging that there are no trade-offs between AEs and efficacy - KOL It can be broadly expanded to a larger subset of patients and deliver great efficacy - KOL Source: Physician market research , Q4 2023; Brainsurgery and IO Biotech (2023); reactions to Ph1/2 data and target product profile
IO Biotech is developing a cancer vaccine aiming to improve patient outcomes, without adding systemic toxicity, focusing on efficacy, durability, safety, and tolerability UNIQUE VALUE PROPOSITION | IO Biotech aims to address the unmet needs of the patients vis-à-vis current therapies Parameter Standard of Care Recently approved therapy Efficacy Safety Tolerability CURRENT THERAPIES IN MELANOMA IOBT’S VALUE PROPOSITION Initials: Initials: 59% of those patients experience severe adverse events2 40% of advanced melanoma patients do not fully benefit from current therapies1 Clinical data showing activity without added systemic toxicity Current anti-PD1 combination therapies for advanced melanoma offer either better efficacy or safety, but not both PATIENT NEEDS 1/10 2/10 3/10 5/10 6/10 7/10 8/10 9/10 10/10 1/10 2/10 3/10 5/10 7/10 8/10 9/10 10/10 Relative disadvantage Relative advantage Patients seek better outcomes, that lead to better treatment responses, not adding systemic toxicity. Sources: Prescribing informations (Opdualag®, Opdivo®, Yervoy®), CHECKMATE-067: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma ; RELATIVITY-047; A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
TECHNOLOGY PLATFORM | T-Win® cancer vaccines have a dual mechanism of action, targeting both tumor cells and immuno-suppressive cells in the TME T cells attack both tumor cells and target-expressing immuno-suppressive cells (e.g., IDO1, PDL1) The modulated and inflamed TME becomes immune permissive, enabling further tumor cell killing by the T cells T-win vaccine activates T cells with a dual mechanism of action Subcutaneous injection with T- win cancer vaccine technology, once every three weeks The T-win® cancer vaccine platform provide new therapeutic strategies that can continue to improve patient outcomes with novel mechanism of action and by addressing multiple TME suppressive elements in solid tumors. Sources: Kjeldsen et al. Nat Med. 2021;27:2212–2223. Erratum in: Nat Med. 2022;28(4):871; (Munir et al. 2012, Munir et al. 2013, Ahmad et al. 2014, Andersen 2019).; (IO Biotech and Lankenau Institute [unpublished data]) ; Andersen, M.H. Semin. Immunopathol. (2023).
IA 3Q-2024 Product candidates Line of therapy/ indication Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways IO102-IO103 Targets: IDO, PD-L1 First Line Advanced Melanoma* Phase 3 pivotal trial fully enrolled; outcome of interim analysis (IA) expected 3Q24. Potential accelerated approval in 2025 if supported by IA IO102–IO103 First Line Solid Tumors* Lung (NSCLC) Head & Neck (SCCHN) Indication expansion strategy in 1L NSCLC and SCCHN on track Neo-adjuvant / Adjuvant Solid Tumors* Melanoma Head & Neck (SCCHN) Extension into earlier lines of treatment; trial enrolling with high level of interest from global sites IO112 Target: Arginase 1 Solid Tumors Indications TBD Research ongoing - Early-stage pipeline targeting additional immuno-suppressive mechanisms IO170 Target: TGF-b1 Solid Tumors Indications TBD Research ongoing - Early-stage pipeline targeting additional immuno-suppressive mechanisms From one-dimension with a single product candidate in one indication… …to a multi-dimensional pipeline testing patients globally on 3 indications and continuing to expand. Ongoing pipeline development PIPELINE | The T-win® cancer vaccine platform with 3 product candidates in multiple cancer indications IA = Interim Analysis, NSCLC = non-small cell lung cancer, SCCHN = squamous cell carcinoma of the head and neck * In combination with pembrolizumab
CLINICAL TRIALS | The totality of clinical data for IO102-IO103 is encouraging Ph1/2 in melanoma (MM1636) with encouraging results, driving continued clinical development à Ph3 in first-line advanced melanoma (IOB-013/KN-D18) Ongoing Ph2 in solid tumors basket (IOB-022/KN-D38) with encouraging preliminary efficacy data; no new safety signals observed FIRST LINE METASTATIC MELANOMA Results from phase 1/2 (MM1636): 80% ORR*, 50% CR Status: Currently in Phase 3 with 380 patients FIRST LINE NSCLC Results from phase 2 ORR 56% > Benchmark ORR 39%** Status Encouraging preliminary data (n=18) presented at ESMO 2023 FIRST LINE SCCHN Results from phase 2 ORR 3/6 > Benchmark ORR 23%** Status Encouraging preliminary data presented at ESMO 2023 From one-dimension with a single product candidate in one indication… …to a multi-dimensional pipeline testing patients globally on 3 indications and continuing to expand. *Two of the 24 responding patients progressed before subsequent radiological confirmation (as previously reported in Nature Medicine RECIST1.1= 73.3% ORR) **KEYNOTE-042 (pembro alone in 1L NSCLC PD-L1 ≥50%): ORR 39%; KEYNOTE-048 (pembro alone in 1L SCCHN CPS ≥20%): ORR 23%
CLINICAL TRIALS | Successful outcomes from phase 1/2 were published in Nature Medicine and drove continued clinical development for 1L melanoma Compelling Data Published in Nature Medicine December 09, 2021 Results showing an attractive safety profile January 2023 Data Cut* as Published in JITC, May 2023 49.8 Months median follow up 25.5 mOS Median Overall Survival Not yet reached 50% 80% 17% CRR Complete Response Rate ORR Overall Response Rate (as previously reported in Nature; RECIST1.1= 73.3% ORR) TRAEs leading to discontinuation** Treatment Related Adverse Events Months mPFS Progression Free Survival Phase 1/2 MM1636 Melanoma * January 23 update: One patient was re-evaluated and did not have “real progression” but instead pseudo progression Lorentzen et al. J Immunother Cancer 2023;11(5):e006755 ** TRAEs were not published in JITC data
NEXT STEPS Pre-defined interim analysis of ORR: First 225 patients 12 months post randomization; Outcome of interim analysis expected in 3Q2024; if supportive, BLA submission for accelerated approval MILESTONES IDMC meeting in September 2023 recommended that the trial continue without modifications; Completed enrolment of 380 patients November 2023 >100 sites enrolling patients in Europe, Australia, South Africa, Israel and the United States PRIMARY ENDPOINT PFS by central review SECONDARY/EXPLORATORY ENDPOINTS ORR, DRR, CRR, OS, DoR, TTR, DCR Incidence of AEs and SAEs Quality of life Biomarkers in blood and tumor tissue will also be assessed Disease Stage (Low vs high risk)* BRAF (mut vs WT) IO102-IO103 and Pembrolizumab 200mg q3w (N= 190) Pembrolizumab 200mg q3w (N= 190) For up to 35 cycles 1:1 *Stage IIID and IV M1a-b vs. stage IV Mic-d Stratification Endpoints Randomization N=380 Advanced Melanoma Unresectable Stage III Metastatic Stage IV > 6 mo. After adj. neo-adjuvant anti-PD-1 Measurable disease (RECIST 1.1) ECOG PS 0-1 Stable CNS disease is allowed Eligibility criteria CLINICAL TRIALS | Treatment for 1L melanoma is currently in ph3, fully enrolled with IA in Q3 24 and potential BLA submission by end of 2024 Phase 3 IOB-013/KN-D18 Melanoma Clinical trial design * IDMC = independent data monitoring committee, BLA = Biologics License Applications (US Food and Drug Administration) ClinicalTrials.gov identifier: NCT05155254
PRIMARY ENDPOINT ORR SECONDARY/EXPLORATORY ENDPOINTS PFS (RECIST1.1) DoR CR DCR OS Safety CLINICAL TRIALS | Treatments for Head & Neck and Lung cancer are currently in phase 2 with encouraging preliminary data 1:1 IO102-IO103 and Pembrolizumab 200mg q3w NSCLC PD- L1 TPS ≥ 50% SCCHN (HPV +/-) PD- L1 CPS ≥ 20 Cohort A = Non-small cell lung cancer adenocarcinoma Cohort B = Squamous cell carcinoma of the head and neck R/M disease For up to 35 cycles N=up to 30 per cohort Previously untreated metastatic solid tumors No prior 1-line therapy Measurable disease ECOG PS 0 or 1 Eligibility criteria Cohorts1 Treatment Endpoints PRELIMINARY RESULTS Encouraging preliminary data from ESMO, with an ORR of 56% for NSCLC and an ORR in 3/6 patients for SCCHN ORR shows potential to compare favorably to market benchmarks: For NSCLC, IOBT’s ORR 56% > Market ORR* 39%; while for SCCHN, IOBT’s ORR 3/6 patients > Market ORR** 23% MILESTONES & NEXT STEPS Achieved pre-defined interim analysis of ORR in NSCLC cohort: First 15 patients with ≥2 cycles and ≥2 post-baseline tumor assessments or discontinued Next steps to get additional data Phase 2 IOB-022/KN-D38 Solid Tumor Basket Clinical trial design *KEYNOTE-042 (pembro alone in 1L NSCLC PD-L1 ≥50%): ORR 39% (Mok et al. Lancet 2019) **KEYNOTE-48 (pembro alone in 1L SCCHN CPS ≥20%): ORR 23% (Burtness et al. Lancet 2019) EudraCT No. 2021-003026-69; ClinicalTrials.gov No. NCT05077709
CLINICAL TRIALS | Preliminary analysis shows 5 NSCLC and 3 SCCHN patient partial responses having more than 180 days PFS Cohort A: NSCLC-adenocarcinoma Cohort B: SCCHN NSCLC results (N=18) SCCHN results (N = 6) Encouraging preliminary data reported Best overall response N = 18 ORR (95% CI)* 56% [30.8; 78.5] Partial Response (PR) 10 (56%) Stable Disease (SD) 5 (28%) Progressive Disease (PD) 3 (17%) Efficacy set: all patients with at least 2 post-baseline tumor assessments or discontinued after 2 cycles of study treatment. Safety profile consistent with previous studies. Note: 8 out of the 10 NSCLC patients and the 3 SCCHN patient had PR confirmed per RECIST 1.1.; patient 035 experienced progressive disease at the following scan and patient 050 had not yet had their second scan at the time of data cut off. Patient 008 discontinued study treatment due to toxicity. Best overall response N = 6 ORR* 3 / 6 Partial Response 3 Stable Disease 0 Progressive Disease 3 Preliminary partial responses, days since first injection per subject A A B B Phase 2 IOB-022/KN-D38 Solid Tumor Basket C = cycle; CI = confidence interval; CR = complete response; ORR = overall response rate; PD = progressive disease; PR, partial response; SD = stable disease; TPS = tumor proportion score
CLINICAL TRIALS | Neo-adjuvant/adjuvant treatment for Melanoma and Head & Neck cancer are currently enrolling a phase 2 1:1 IO102-IO103 and Pembrolizumab (200mg q3w) Melanoma Resectable Stage III SCCHN Resectable Stage III/IV N= 15 per cohort Resectable melanoma or SCCHN Candidate for surgical resection with curative intent No prior therapy for the tumor under study Measurable disease ECOG PS 0 or 1 Eligibility criteria Cohorts Treatment Trial open for enrollment at sites in countries including Australia, US, France, Germany & Spain First patient treated in December 2023 Phase 2 IOB-032/KN-D40 Neo-adjuvant/adjuvant Basket Trial Clinical trial design Neo-adjuvant phase 2-3 cycles Surgical resection Surgery and recovery Recovery* IO102-IO103 and Pembrolizumab q3w 15 cycles Adjuvant phase 3 cycles * Recovery ≤12 weeks; ** If required ECOG PS, Eastern Cooperative Oncology Group performance status; SCCHN, squamous cell carcinoma of the head and neck ClinicalTrials.gov No. NCT05280314 Recovery* followed by SoC RT+/- cisplatin** No CRT Primary endpoint: Major pathologic response Secondary endpoints: Pathological CR, ORR Other secondary endpoints: DFS, EFS, Safety Milestones and next steps Endpoints
TIME TO TREATMENT | IOBT’s off-the-shelf therapeutic cancer vaccines ensure patients can receive treatment without delay* GMP Manufacturing Vaccine production Storage The vaccine is stored at 2-8°C Procurement The vaccine is ordered by the clinic Patient Vaccination The patient receives the vaccine A 4 steps process from IO102-IO103 production to the patient vaccination… Time to treatment IOBT’s therapeutic cancer vaccine provides fast access to the medicine ensuring the patients don’t have to wait* … Enhancing the overall patient experience. No additional visits necessary for treatment The patient needs to be in the clinic once every three weeks for the vaccine administration aligned with current SOC** * Compared to a personalized vaccine ** E.g. anti PD-1 treatment
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
IOB-022 – basket trial data GROWTH STRATEGY | Since its foundation in 2014, IO Biotech has built a strong platform and has the potential for US market launch in 2025 Company Founded MM1636@CCIT (IDO and PD-L1 peptides) starts showing impressive data FDA grants BTD designation MM1636 data presented at ESMO as LBA Nature Medicine Publication $150 million Series B $100 million IPO Expanded US presence with corporate office in NYC and research hub in MD Initiated IOB-022 – ph 2 basket trial Initiated IOB-013 – ph 3 pivotal trial IOB-022 – ph2 encouraging preliminary data Board and investments Clinical trials development IOB-013 Interim Analysis IOB-013 – ph 3 complete enrollment Potential BLA submission depending on IA outcome Potential accelerated approval in the US depending on IA outcome Significant upcoming milestones Building a strong platform and initiating clinical trials Company creation and securing financing 2021 2020 2014 2022 2023 2024 2025 IOB-032 – ph 2 neo-adjuvant/ adjuvant study initiated
GROWTH STRATEGY | The aim is to use our first mover advantage in melanoma and expand into multiple cancer types and earlier settings Building a solid science platform with a unique value proposition Immune-modulating cancer vaccine targeting both the tumor and the immune suppressive cells Significant clinical milestone and potential launch Phase 3 pivotal trial in 1st line advanced melanoma ongoing with interim analysis outcome expected 3Q2024 and potential BLA submission for accelerated approval based on interim analysis New programs targeting earlier lines of melanoma, multiple upside opportunities in other solid tumors (NSCLC and SCCHN), and early-stage pipeline targeting additional immune suppressive mechanisms Expansion into multiple opportunities 2025 2028 EXPAND BUILDING LAUNCH 2014 - 2023 Potential use of the T-Win technology into other types of diseases, such as infectious, inflammatory, and auto-immune diseases* Exploring the use of the T-Win technology to cure other diseases Future EXPLORE *Source: The Lancet Journal October 26, 2022; thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00300-7/fulltext
OUTLOOK | Important clinical milestones expected in the next two years, supported by $165.5 M* cash runway into 4Q2025 Program Phase Indication Line of therapy IO102-IO103 Targets: IDO, PD-L1 Phase 3 Melanoma First-line advanced IO102–IO103 Phase 2 Basket trials Lung (NSCLC) Head & Neck (SCCHN) First-line metastatic Phase 2 Basket trials Melanoma Head & Neck (SCCHN) Neo-adjuvant / adjuvant IO112 Target: Arginase 1 Phase 1/2 Solid Tumors IO170 Target: TGF-b1 Solid Tumors Milestones through 2024 Milestones through 2025 225 patients enrolled June 2023 Complete enrollment by year-end 2023 Interim analysis (IA) 2Q2024, outcome 3Q24 Potential accelerated approval in the U.S. if supported by IA Primary endpoint of progression free survival expected to be reached in 2H25 Additional data Final data Initiate Phase 2 in 2H2023 Initial data IND ready IND filing; Initiate IST study Pre-clinical studies IND enabling studies Potential BLA submission based on IA * As of Sept 30, 2023.
PATIENT AND MARKET PERSPECTIVE 1 OUR UNIQUE VALUE PROPOSITION 2 OUR PIPELINE AND THE SCIENCE BEHIND IT 3 GROWTH STRATEGY AND OUTLOOK 4 THE IO BIOTECH TEAM 5 CONTENT
THE TEAM | We have a strong management team with large biopharma and biotech experience Mai-Britt Zocca, Ph.D. Chief Executive Officer Qasim Ahmad, M.D. Chief Medical Officer Amy Sullivan, M.B.A. Chief Financial Officer Eric Faulkner, M.B.A. Chief Technical Officer Devin Smith General Counsel Dan Mannix, Ph.D. SVP Regulatory
Board of Directors THE TEAM | Our management team is supported by the Board of Directors and the Scientific Advisory Board Peter Hirth, Ph.D. Chairman Kathleen Sereda Glaub, M.B.A. Member Christian Elling, Ph.D. Member – Lundbeckfonden Heidi Hunter Member Jack B. Nielsen, M.Sc Member – Vivo Capital David V. Smith, M.B.A. Member Mai-Britt Zocca, Ph.D. President and CEO Scientific Advisory Board Inge Marie Svane, M.D., Ph.D Founder, Clinical Advisor Alexander Eggermont, M.D., Ph.D. Sr. Clinical Advisor Kapil Dhingra, M.D. Strategic R&D Advisor Mads Hald Andersen, M.D., Ph.D. Founder, Scientific Advisor Hellen Collins, M.D. Member
Indications: Melanoma SCCHN NSCLC 3 T-win cancer vaccine technology platform 1 3 Pipeline programs 17 Patent Families Focused on improving clinical effect without adding systemic toxicity 50% 80% * Results from phase 1/2 MM1636 Melanoma 25.5 Months mPFS* Providing rapid and durable responses HIGHLIGHTS | Break Boundaries. Ignite Change. 3Q24 Ph. 3 interim analysis outcome IO102-IO103 in Ph. 3 Pivotal trial in advanced melanoma fully enrolled 2025 Potential US market entry ORR* CRR*